Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery-Reference-Cited by-同舟云学术

Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery

Published:2021-07-01 Issue:9 Volume:60 Page:1114-1121
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Terlizzi Mario¹^ORCID,Buscail Etienne²,Boussari Olayidé³,Adgié Sarah¹,Leduc Nicolas¹,Terrebonne Eric⁴,Smith Denis⁴,Blanc Jean-Frédéric⁴,Lapuyade Bruno⁵,Laurent Christophe²,Chiche Laurence²,Belleannée Geneviève⁶,Le Malicot Karine³,Trouette Renaud¹,Pouypoudat Claudia¹,Vendrely Véronique¹²³⁴⁵

Affiliation:

1. Service de Radiothérapie, CHU Bordeaux, Bordeaux, France

2. Département de Chirurgie, CHU Bordeaux, Bordeaux, France

3. Département de Biostatistiques, FFCD, Dijon, France

4. Service d’Oncologie Médicale, CHU Bordeaux, Bordeaux, France

5. Département d’Imagerie Médicale, CHU Bordeaux, Bordeaux, France

6. Service d’Anatomopathologie, CHU Bordeaux, Bordeaux, France

Publisher

Informa UK Limited

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link